KalVista Pharmaceuticals Reports $40.9M Revenue in Latest Quarter, Enters Merger Agreement with Chiesi

KalVista Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenues of $40.9 million, a substantial increase from zero in the same period last year, primarily driven by the commercial launch of its lead product, EKTERLY® (sebetralstat), which received FDA approval in July 2025. Product revenue accounted for $39.2 million, while partnership and other revenue contributed $1.7 million, reflecting the company's expanding market presence.

In terms of expenses, KalVista's total operating expenses rose to $64.3 million, up from $49.7 million in the prior year, marking a 29% increase. This rise was largely attributed to a 37% increase in selling, general, and administrative expenses, which reached $48.8 million, driven by higher personnel and marketing costs. Research and development expenses decreased by 12% to $12.4 million, indicating a strategic shift in resource allocation as the company focuses on commercialization efforts. The operating loss for the quarter was $23.4 million, a notable improvement from a loss of $49.7 million in the same quarter last year.

KalVista's balance sheet as of March 31, 2026, showed total assets of $328.9 million, a slight decrease from $335.4 million at the end of 2025. The company reported cash and cash equivalents of $213.8 million, down from $229.3 million, while marketable securities increased marginally to $71.3 million. The accumulated deficit grew to $786.2 million, reflecting ongoing investments in product development and commercialization. The company’s liabilities also increased, totaling $348.6 million, primarily due to a rise in accrued expenses and royalty obligations.

Strategically, KalVista has made significant moves to enhance its market position. The company entered into a merger agreement with Chiesi Farmaceutici S.p.A. on April 29, 2026, which is expected to close in the third quarter of 2026. Under the terms of the agreement, Chiesi will acquire all outstanding shares of KalVista for $27.00 per share. This merger is anticipated to provide additional resources and support for KalVista's ongoing commercialization efforts, particularly for EKTERLY, which is now marketed in the U.S., Germany, and through partnerships in Japan and other countries.

Looking ahead, KalVista anticipates continued losses as it invests in the commercialization of EKTERLY and navigates the complexities of the pharmaceutical market. The company has indicated that it expects to maintain sufficient funding to support its operations for at least the next twelve months, bolstered by its cash reserves and potential future financing options. The successful execution of the merger with Chiesi is also expected to play a crucial role in shaping the company's future growth trajectory.